|
WO2015024992A2
|
|
Treatment of asthma
|
|
AU2013204626A1
|
|
Immunostimulatory nucleic acid packaged particles for the treatment of hypersenstivity
|
|
AU2013202547A1
|
|
Interleukin-1 conjugates and uses thereof
|
|
WO2011023680A2
|
|
Processes for the synthesis and purification of heterobifunctional cross-linkers
|
|
EP2424570A1
|
|
Influenza hemagglutinin compositions and uses thereof
|
|
WO2010122164A1
|
|
VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
|
|
US2011097417A1
|
|
Melan-a-carrier conjugates
|
|
CN102014952A
|
|
Vaccine compositions for the treatment of dengue fever and uses thereof
|
|
CN101959526A
|
|
Use of interleukin-1 conjugates in the treatment of diabetes
|
|
AU2008339904A1
|
|
Nerve growth factor conjugates and uses thereof
|
|
WO2009080781A1
|
|
Process for clarifying cell homogenates
|
|
WO2009056651A1
|
|
Angiotensin-carrier formulation
|
|
WO2009068335A1
|
|
Human monoclonal nicotine specific antibodies
|
|
EP2121007A1
|
|
Circular ccr5 peptide conjugates and uses thereof
|
|
WO2008071774A1
|
|
Purification process for coat protein of rna bacteriophages
|
|
CN101611048A
|
|
Oligonucleotides containing high concentrations of guanine monomers
|
|
EP2065398A1
|
|
Human monoclonal nicotine specific antibodies
|
|
EP2032592A1
|
|
Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
|
|
EP1982729A1
|
|
Vaccination Regimen for B-Cell Vaccines
|
|
CA2664418A1
|
|
Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
|
